Plain-English translation of NCT06026111 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lung Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether exercise—done at either high or moderate intensity—can help people with non-small cell lung cancer who are receiving anti-PD-1 or anti-PD-L1 immunotherapy. Researchers want to see if regular exercise helps improve fitness, physical strength, and how well the medication works, while reducing unwanted side effects.
People undergoing immunotherapy for lung cancer often experience fatigue and loss of physical function. This study explores whether structured exercise during treatment can help patients stay stronger, recover better, and potentially improve their response to the medication.
You likely qualify if…
You likely don't qualify if…
You'll be randomly placed into one of three groups for 12 weeks. If assigned to exercise, you'll do three supervised workout sessions per week on a stationary bike at home—either with short bursts of intense effort followed by recovery (high-intensity), or at a steady moderate pace (moderate-intensity). The usual care group will continue their normal routine. All participants will have tests to measure fitness, strength, and how the medication is working.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States